Università degli Studi di Cagliari
Incidence of Sarcoma in Patients Undergoing Hysterectomy for Benign Indications: A Population-Based Study
Angioni, StefanoMembro del Collaboration Group
;
2019-01-01
Abstract
Minimally invasive hysterectomy may require the use of morcellation to remove the uterus. In the presence of unexpected sarcoma, morcellation risks disseminating malignant cells and worsening survival outcomes. As a consequence, in 2014 the US Food and Drug Administration (FDA) issued a black box warning against the use of power morcellator for the treatment of uterine fibroids. However, the proportion of unexpected sarcoma at the time of hysterectomy for presumed benign indication remains unclear.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
| Mutinu Am J Ob Gyn 2019.pdf Solo gestori archivio
Tipologia: versione editoriale
Dimensione 508.59 kB
Formato Adobe PDF
|
508.59 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.